A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Name: A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
Published: 2022
License: Public Domain

Merck Sharp & Dohme LLC · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

renalcellcarcinoma

renal cell carcinoma, programmed cell death ligand 1 (pd-l1), hypoxia inducible factor 2 alpha (hif-2 alpha), hypoxia inducible factor 2α (hif-2α), renal cell carcinoma (rcc), kidney cancer, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Related documents